Kura Oncology, Inc.

Listed Company

KURACIK 0001422143NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$67.48M

Net Income

$-278.67M

Total Assets

$738.36M

Equity

$174.13M

Shares Out

88.33M

Op. Cash Flow

$-64.06M

Business

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and aims to commercialize precision small-molecule medicines for oncology. Its main product candidates include ziftomenib, a selective menin‑KMT2A protein‑protein interaction inhibitor, KO‑2806, a next‑generation farnesyl transferase inhibitor (FTI), and tipifarnib, an orally bioavailable FTI, alongside discovery-stage programs and companion diagnostic pairing. The company organizes its activities around menin inhibitor and FTI programs, clinical development and translational research, and strategic collaborations and licensing. It distributes and conducts clinical trials globally, working with partners, investigators and third‑party manufacturers and diagnostic developers.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	67	54	0	—	—
Cost of product sales	57,000	0	0	—	—
Research and development	251	170	115	93	85
Selling, general and administrative	120	77	51	—	—
Total operating expenses	371	247	166	140	131
Loss from operations	−304	−193	−166	−140	—
Interest and other income, net	27	23	15	4	1
Interest expense	−2	−2	−2	−229,000	—
Total other income, net	25	21	13	4	792,000
Loss before income taxes	−278	−172	−153	−136	—
Income tax expense	297,000	2	0	0	—
Net Loss	−279	−174	−153	−136	−130
Net loss per share, basic	−3.18	−2.02	−2.08	−2.03	−1.97
Net loss per share, diluted	−3.18	−2.02	−2.08	−2.03	−1.97
Weighted average number of shares used in computing net loss per share, basic	88	86	73	67	66
Weighted average number of shares used in computing net loss per share, diluted	88	86	73	67	66
Unrealized gain on short-term investments	260,000	2	7	—	—
Comprehensive loss	−278	−172	−146	−142	−132

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	149	224	37	52	91
Short-term investments	518	503	387	386	427
Accounts receivable, net	9	2	—	—	—
Inventory	413,000	0	—	—	—
Prepaid expenses and other current assets	32	15	9	8	4
Total current assets	709	745	432	446	522
Property and equipment, net	8	2	2	3	3
Operating lease right-of-use assets	7	6	7	4	6
Other long-term assets	15	8	8	3	3
Total assets	738	760	449	456	534
Accounts payable	5	1	—	—	—
Accrued expenses and other current liabilities	62	48	—	—	—
Current operating lease liabilities	1	2	2	2	2
Current portion of long-term debt	0	3	—	—	—
Current portion of contract liabilities	49	24	—	—	—
Total current liabilities	117	79	35	24	22
Long-term debt, net of current portion	10	7	9	9	—
Long-term operating lease liabilities	9	5	6	3	5
Other long-term liabilities	3	2	705,000	265,000	375,000
Long-term contract liabilities	425	254	—	—	—
Total liabilities	564	347	52	36	27
Commitments and contingencies (Note 9)	—	—	—	—	—
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding	—	—	—	—	—
Common stock, $0.0001 par value; 200,000 shares authorized; 87,855 and 78,229 shares issued and outstanding as of December 31, 2025 and 2024, respectively	9,000	8,000	7,000	7,000	7,000
Additional paid-in capital	1,347	1,308	1,120	997	941
Accumulated other comprehensive income	1	764,000	−1	−8	−2
Accumulated deficit	−1,174	−895	−721	−569	−433
Total stockholders' equity	174	414	397	420	507
Total liabilities and stockholders' equity	738	760	449	456	534

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation expense	37	34	28	26	24
Amortization of premium and accretion of discounts on short-term investments, net	−8	−13	−9	2	4
Depreciation expense	1	800,000	800,000	800,000	600,000
Non-cash interest expense	515,000	523,000	477,000	73,000	399,000
Accounts receivable, net	−7	−2	0	—	—
Inventory	−413,000	0	0	—	—
Prepaid expenses and other current assets	−16	−7	−2	−3	−357,000
Accounts payable	4	−2	−924,000	—	—
Accrued expenses and other current liabilities	13	17	11	—	—
Operating lease right-of-use and other long-term assets	−6	947,000	−685,000	571,000	−329,000
Other long-term liabilities	1	758,000	137,000	184,000	−20,000
Contract liabilities	196	278	0	—	—
Net cash (used in) provided by operating activities	−64	134	−125	−110	−105
Purchases of short-term investments	−762	−659	−410	−271	—
Maturities of short-term investments	755	558	426	304	—
Purchases of property and equipment	−7	−472,000	−168,000	−626,000	−1
Net cash (used in) provided by investing activities	−13	−102	16	33	−127
Proceeds from issuance of stock under equity plans	2	9	1	4	4
Proceeds from issuances of common stock and pre-funded warrants, net of offering costs	0	146	94	25	—
Net cash provided by financing activities	2	154	95	39	−3
Net (decrease) increase in cash and cash equivalents	−75	187	−14	−39	−235
Interest paid	998,000	1	1	73,000	784,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro